{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-3BO8FT9Y/60f55dec-de8f-4c6b-a649-b554895ce4f0/PDF","dcterms:extent":"517 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-3BO8FT9Y/4133f8b1-a554-4bbb-84bb-31e8bfa1ff1d/TEXT","dcterms:extent":"55 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-3BO8FT9Y","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2024","dc:creator":"Savšek, Lina","dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:75"},{"@xml:lang":"sl","#text":"str. 105-118"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:203811843","URN:URN:NBN:SI:doc-3BO8FT9Y"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"Multipla skleroza"},{"@xml:lang":"sl","#text":"Multiple sclerosis"},{"@xml:lang":"sl","#text":"Terapija"},{"@xml:lang":"sl","#text":"Therapy"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Sodobni pristop k zdravljenju multiple skleroze| Modern approach to treating multiple sclerosis|"},"dc:description":[{"@xml:lang":"sl","#text":"The progression of multiple sclerosis is driven by the intertwined dynamics of immune-mediated neuroinflammation and neurodegeneration, making it the leading cause of nontraumatic neurological disability in young adults. A modern treatment approach necessitates a clear definition of the disease course, identification of prognostic factors, and early personalized intervention. The primary treatment goals focus on slowing neuroinflammation and neurodegeneration to reduce long-term disability and enhance quality of life. Although early use of high-efficacy disease-modifying treatments correlates with improved long-term outcomes, it poses higher safety risks. Factors influencing therapy choice include drug efficacy and safety, neurological disability, clinical and radiologic disease activity, comorbidities, and patient preferences, including family planning. Comprehensive knowledge of disease-modifying treatment mechanisms and monitoring protocols is crucial to mitigate associated risks"},{"@xml:lang":"sl","#text":"Bolezenski proces multiple skleroze sestavljajo tesno povezano imunsko pogojeno vnetje, demielinizacija in propad živčnih celic, kar pomembno prispeva k napredujoči naravi bolezni in jo uvršča med vodilne vzroke invalidnosti pri mladih odraslih. Sodobni pristop k zdravljenju multiple skleroze zahteva dobro opredelitev oblike poteka bolezni, dejavnikov tveganja za težji potek in napredovanje bolezni ter čimprejšnjo personalizirano izbiro zdravljenja. Cilj zdravljenja je upočasnitev vnetnega in nevrodegenerativnega procesa bolezni z namenom zmanjšanja invalidnosti in ohranjanja kvalitete življenja. Z zgodnjo uporabo učinkovitih zdravil se prognoza oseb z multiplo sklerozo pomembno izboljšuje, a so z njihovo uporabo lahko povezana tudi večjatveganja. Pri izbiri zdravljenja je potrebno upoštevati številne dejavnike, med drugim učinkovitost in varnostni profil zdravila, nevrološko prizadetost, klinično in radiološko aktivnost bolezni, bolnikove pridružene bolezni ter njegove želje, vključno z načrtovanjem družine. Dobro poznavanje mehanizmov delovanja zdravil in izdelane strategije spremljanja so ključne za uspešno obvladovanje tveganj, povezanih z zdravljenjem"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-3BO8FT9Y","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-3BO8FT9Y"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-3BO8FT9Y/60f55dec-de8f-4c6b-a649-b554895ce4f0/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-3BO8FT9Y/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-3BO8FT9Y"}}}}